Patient, cord blood, and transplant characteristics of 1375 patients with hematologic malignancies undergoing DUCBT from 2006 to 2017
| Characteristics . | Values (N = 1375) . |
|---|---|
| Male, n (%) | 805 (59) |
| Median age (range), y | 48 (18-73) |
| Median body weight (range), kg* | 71 (40-150) |
| Positive cytomegalovirus serology, n (%) | 776 (59) |
| Disease type, n (%) | |
| Acute leukemia | 791 (57) |
| Lymphoma | 270 (20) |
| Myelodysplastic syndrome | 143 (10) |
| Myeloproliferative disorder | 90 (7) |
| Others† | 81 (6) |
| Disease status, n (%) | |
| Early | 420 (31) |
| Intermediate | 426 (31) |
| Advanced | 400 (29) |
| Not reported | 129 (9) |
| Median cryopreserved cells (IQR) | |
| TNCs, 107/kg | 5.1 (4.3, 6.0) |
| Total CD34+ cells, 105/kg‡ | 1.9 (1.4, 2.7) |
| Median infused cells (IQR) | |
| TNCs, 107/kg | 3.9 (3.0, 4.8) |
| Total CD34+ cells, 105/kg‡ | 1.4 (0.9, 2.0) |
| HLA compatibility, n (%)§ | |
| 6 of 6 | 18 (1) |
| 5 of 6 | 373 (27) |
| 4 of 6 | 851 (62) |
| 3 of 6 | 91 (7) |
| 2 of 6 | 6 (0) |
| Not reported | 36 (3) |
| ABO compatibility, n (%)|| | |
| Compatible | 224 (16) |
| Minor incompatibility | 394 (39) |
| Major incompatibility | 654 (48) |
| Not reported | 103 (7) |
| Interunit ABO match, n (%) | |
| Matched | 565 (41) |
| Interunit sex match, n (%) | |
| Matched | 703 (51) |
| GVHD prophylaxis, n (%) | |
| Cyclosporine and mycophenolate | 1045 (76) |
| Others | 330 (24) |
| Conditioning intensity, n (%) | |
| Reduced-intensity conditioning | 929 (68) |
| Myeloablative conditioning | 408 (30) |
| Not reported | 38 (3) |
| Conditioning regimens, n (%) | |
| Cyclophosphamide + fludarabine + TBI, low dose | 728 (53) |
| Cyclophosphamide + fludarabine + TBI, high dose | 181 (13) |
| Cyclophosphamide + TBI, high dose | 66 (5) |
| Others | 342 (25) |
| Not reported | 58 (4) |
| Use of antithymocyte globulin, n (%) | 316 (28) |
| Year of transplant, n (%) | |
| ≥2012 | 552 (40) |
| Characteristics . | Values (N = 1375) . |
|---|---|
| Male, n (%) | 805 (59) |
| Median age (range), y | 48 (18-73) |
| Median body weight (range), kg* | 71 (40-150) |
| Positive cytomegalovirus serology, n (%) | 776 (59) |
| Disease type, n (%) | |
| Acute leukemia | 791 (57) |
| Lymphoma | 270 (20) |
| Myelodysplastic syndrome | 143 (10) |
| Myeloproliferative disorder | 90 (7) |
| Others† | 81 (6) |
| Disease status, n (%) | |
| Early | 420 (31) |
| Intermediate | 426 (31) |
| Advanced | 400 (29) |
| Not reported | 129 (9) |
| Median cryopreserved cells (IQR) | |
| TNCs, 107/kg | 5.1 (4.3, 6.0) |
| Total CD34+ cells, 105/kg‡ | 1.9 (1.4, 2.7) |
| Median infused cells (IQR) | |
| TNCs, 107/kg | 3.9 (3.0, 4.8) |
| Total CD34+ cells, 105/kg‡ | 1.4 (0.9, 2.0) |
| HLA compatibility, n (%)§ | |
| 6 of 6 | 18 (1) |
| 5 of 6 | 373 (27) |
| 4 of 6 | 851 (62) |
| 3 of 6 | 91 (7) |
| 2 of 6 | 6 (0) |
| Not reported | 36 (3) |
| ABO compatibility, n (%)|| | |
| Compatible | 224 (16) |
| Minor incompatibility | 394 (39) |
| Major incompatibility | 654 (48) |
| Not reported | 103 (7) |
| Interunit ABO match, n (%) | |
| Matched | 565 (41) |
| Interunit sex match, n (%) | |
| Matched | 703 (51) |
| GVHD prophylaxis, n (%) | |
| Cyclosporine and mycophenolate | 1045 (76) |
| Others | 330 (24) |
| Conditioning intensity, n (%) | |
| Reduced-intensity conditioning | 929 (68) |
| Myeloablative conditioning | 408 (30) |
| Not reported | 38 (3) |
| Conditioning regimens, n (%) | |
| Cyclophosphamide + fludarabine + TBI, low dose | 728 (53) |
| Cyclophosphamide + fludarabine + TBI, high dose | 181 (13) |
| Cyclophosphamide + TBI, high dose | 66 (5) |
| Others | 342 (25) |
| Not reported | 58 (4) |
| Use of antithymocyte globulin, n (%) | 316 (28) |
| Year of transplant, n (%) | |
| ≥2012 | 552 (40) |
GVHD, graft-versus-host disease; IQR, interquartile range; TBI, total-body irradiation.
Information missing for 2 cases.
Plasma cell and myelodysplastic/myeloproliferative disorders.
Information was missing for 69 cases.
HLA-A and B at low and HLA-DRB1 at high-resolution levels. Cord blood unit with the highest HLA disparity in relation to the patient. Information on the number of mismatches (ie, ≤1 or >1) was available for all patients.
Cord blood unit with the highest ABO disparity in relation to the patient.